新型抗凝药物的研究进展

刘英明; 杨晔

doi:10.13201/j.issn.1001-1439.2012.07.027

新型抗凝药物的研究进展

刘英明^,,
杨晔

- 中国人民解放军海军总医院心内科(北京, 100048)

详细信息

通讯作者: 刘英明,E-mail:ltlyingming@163.com

中图分类号: R541.7

收稿日期: 2011-06-17

Progress in investigation of new anticoagulants

LIU Yingming^,,
YANG Ye

- Department of Cardiology, Navy General Hospital of PLA, Beijing, 100048, China

More Information

Corresponding author: LIU Yingming, E-mail: ltlyingming@163.com

Received Date: 17 June 2011

摘要

摘要: 华法林在临床应用有一定局限性,需要有新的抗凝剂来代替。本文主要对新近出现的抗凝药物,如直接Xa因子抑制剂、直接凝血酶抑制剂和新型维生素K拮抗剂作一综述。
- 华法林 /
- 直接Xa因子抑制剂 /
- 直接凝血酶抑制剂 /
- 维生素K拮抗剂
Abstract: Warfarin has variable and unpredictable antithrombotic effect,and needs regular monitoring and dose adjustment.So it is necessary to investigate alternative drugs for warfarin.Some new anticoagulants including direct factor Xa inhibitors,direct thrombin inhibitors and novel vitamin K antagonist were reviewed in this article.
- warfarin /
- direct Xa inhibitor /
- direct thrombin inhibitor /
- vitamin K antagonist

HTML全文

参考文献(12)

[1]	TURPIE A G.New oral anticoagulants in atrial fibril-lation[J].Eur Heart J,2008,29:155-165.
[2]	ZIKRIA J C, ANSELL J. Oral anticoagulation with factor Xa and thrombin inhibitors:on the threshold of change[J]. Curr Opin Hematol,2009,16:347-356.
[3]	KAKKAR A K,BRENNER B,DAHL O E,et al.Ex-tended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:A double-blind,randomised controlled trial[J].Lancet,2008,372:31-39.
[4]	Executive Steering Committee on behalf of the ROCK-ET AF Study Investigators.Rivaroxaban-once daily,oral,direct factor Xa inhibition compared with vita-min K antagonism for prevention of stroke and embol-ism trial in atrial fibrillation:rationale and design of the ROCKET AF Study[J].Am Heart J,2010,159:340-347.
[5]	CLELAND J G,COLETTA A P,BUGA L,et al.Clinical trials update from the American Heart Asso-ciation Meeting2010:EMPHASIS-HF,RAFT,TIM-HF,Tele-HF,ASCEND-HF,ROCKET-AF,and PROTECT[J].Eur J Heart Fail,2011,13:460-465.
[6]	CARREIRO J, ANSELL J. Apixaban, an oral direct factor Xa inhibitor:awaiting the verdict[J]. Exp Opin Invest Drugs,2008,17:1937-1945.
[7]	SAMAMA M M,GEROTZIAFAS G T.Newer anti-coagulants in2009[J].J Thromb Thrombolysis,2010,29:92-104.
[8]	STANGIER J.Clinical pharmacokinetics and pharma-codynamics of the oral direct thrombin inhibitor dabig-atran etexilate[J].Clin Pharmacokinet,2008,47:285-295.
[9]	WEITZ J I,HIRSH J,SAMAMA M M.New an-tithrombotic drugs:american college of chest physi-cians evidence-based clinical practice guidelines(8th Edition)[J].Chest,2008,133:234S-256S.
[10]	CONNOLLY S J, EZEKOWITZ M D, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361:1139-1151.
[11]	ANSELL J.Warfarin versus new agents:interpreting the data[J].Hematol Am Soc Hematol Educ Pro-gram,2010,201:221-228.
[12]	ELLIS D J,USMAN M H,MILNER P G,et al.The first evaluation of a novel vitamin K antagonist,tecarfarin(ATI-5923),in patients with atrial fibrilla-tion[J].Circulation,2009,120:1029-1035.